The Involvement of Nano-Drug Delivery in Biosafety Issues

Autores
Romero, Eder Lilia
Año de publicación
2012
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Nanotechnology encompasses a broad conjunct of techniques aimed to engineer, characterize and make use of structures of 1 (nanoplates), 2 (nanotubes) or 3 dimensions (nanoparticles) in the nanoscale, known as nano-objects. The upper limit of the nanoscale was fixed at 100 nm [1], but in the nanopharmaceutical field the nano-scale is accepted to rise up to 200-300 nm. Biosynthesized molecules (such as hormones, proteins, nucleic acids) and drugs, whose activity depends on a primary structure and not on new phenomena derived from its size in the nano-scale, do not fit into the definition of nano-object [2]. Also the lower limit of the nanoscale was fixed in 1 nm in order to exclude atoms [2]. Beyond these constraints, there is no restriction in chemical nature of nano-objects. Today, the global market of nanotechnological consumer product is gained by non biodegradable and mostly nondispersive nano-objects. This is underscored by the raise from 212 to 1317 products (nearly 521%) between 2006 and 2011 [3]. On the other hand, Nanomedicine is the emerging discipline that employs nanoobjects as tools to solve medical problems [4,5]. The volume market of Nanomedicine is expected to exceed $160 billion by 2015, according to a business report recently launched by the Global Industry Analysts Inc [6]. The main technological platform of Nanomedicine is nano-drug delivery, accounting for 78 % global sales and 58 % of patent filling worldwide [7,8] followed by development of nano-objects for in vitro/in vivo diagnosis [9] and tissue engineering [10]. The field is characterized by the advent of a different type of nano-objects, inherently dispersive or ‘free’.
Fil: Romero, Eder Lilia. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Materia
BIOSAFETY
DRUG DELIVERY SYSTEMS
NANOPARTICLES
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/195353

id CONICETDig_52acced3769985fdebee466e17df191c
oai_identifier_str oai:ri.conicet.gov.ar:11336/195353
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling The Involvement of Nano-Drug Delivery in Biosafety IssuesRomero, Eder LiliaBIOSAFETYDRUG DELIVERY SYSTEMSNANOPARTICLEShttps://purl.org/becyt/ford/2.10https://purl.org/becyt/ford/2Nanotechnology encompasses a broad conjunct of techniques aimed to engineer, characterize and make use of structures of 1 (nanoplates), 2 (nanotubes) or 3 dimensions (nanoparticles) in the nanoscale, known as nano-objects. The upper limit of the nanoscale was fixed at 100 nm [1], but in the nanopharmaceutical field the nano-scale is accepted to rise up to 200-300 nm. Biosynthesized molecules (such as hormones, proteins, nucleic acids) and drugs, whose activity depends on a primary structure and not on new phenomena derived from its size in the nano-scale, do not fit into the definition of nano-object [2]. Also the lower limit of the nanoscale was fixed in 1 nm in order to exclude atoms [2]. Beyond these constraints, there is no restriction in chemical nature of nano-objects. Today, the global market of nanotechnological consumer product is gained by non biodegradable and mostly nondispersive nano-objects. This is underscored by the raise from 212 to 1317 products (nearly 521%) between 2006 and 2011 [3]. On the other hand, Nanomedicine is the emerging discipline that employs nanoobjects as tools to solve medical problems [4,5]. The volume market of Nanomedicine is expected to exceed $160 billion by 2015, according to a business report recently launched by the Global Industry Analysts Inc [6]. The main technological platform of Nanomedicine is nano-drug delivery, accounting for 78 % global sales and 58 % of patent filling worldwide [7,8] followed by development of nano-objects for in vitro/in vivo diagnosis [9] and tissue engineering [10]. The field is characterized by the advent of a different type of nano-objects, inherently dispersive or ‘free’.Fil: Romero, Eder Lilia. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaOMICS GROUP2012-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/195353Romero, Eder Lilia; The Involvement of Nano-Drug Delivery in Biosafety Issues; OMICS GROUP; Biosafty; 1; 2; 3-2012; 1-52167-0331CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.longdom.org/open-access/the-involvement-of-nanodrug-delivery-in-biosafety-issues-2167-0331.1000e108.pdfinfo:eu-repo/semantics/altIdentifier/doi/10.4172/2167-0331.1000e108info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:57:15Zoai:ri.conicet.gov.ar:11336/195353instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:57:16.24CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv The Involvement of Nano-Drug Delivery in Biosafety Issues
title The Involvement of Nano-Drug Delivery in Biosafety Issues
spellingShingle The Involvement of Nano-Drug Delivery in Biosafety Issues
Romero, Eder Lilia
BIOSAFETY
DRUG DELIVERY SYSTEMS
NANOPARTICLES
title_short The Involvement of Nano-Drug Delivery in Biosafety Issues
title_full The Involvement of Nano-Drug Delivery in Biosafety Issues
title_fullStr The Involvement of Nano-Drug Delivery in Biosafety Issues
title_full_unstemmed The Involvement of Nano-Drug Delivery in Biosafety Issues
title_sort The Involvement of Nano-Drug Delivery in Biosafety Issues
dc.creator.none.fl_str_mv Romero, Eder Lilia
author Romero, Eder Lilia
author_facet Romero, Eder Lilia
author_role author
dc.subject.none.fl_str_mv BIOSAFETY
DRUG DELIVERY SYSTEMS
NANOPARTICLES
topic BIOSAFETY
DRUG DELIVERY SYSTEMS
NANOPARTICLES
purl_subject.fl_str_mv https://purl.org/becyt/ford/2.10
https://purl.org/becyt/ford/2
dc.description.none.fl_txt_mv Nanotechnology encompasses a broad conjunct of techniques aimed to engineer, characterize and make use of structures of 1 (nanoplates), 2 (nanotubes) or 3 dimensions (nanoparticles) in the nanoscale, known as nano-objects. The upper limit of the nanoscale was fixed at 100 nm [1], but in the nanopharmaceutical field the nano-scale is accepted to rise up to 200-300 nm. Biosynthesized molecules (such as hormones, proteins, nucleic acids) and drugs, whose activity depends on a primary structure and not on new phenomena derived from its size in the nano-scale, do not fit into the definition of nano-object [2]. Also the lower limit of the nanoscale was fixed in 1 nm in order to exclude atoms [2]. Beyond these constraints, there is no restriction in chemical nature of nano-objects. Today, the global market of nanotechnological consumer product is gained by non biodegradable and mostly nondispersive nano-objects. This is underscored by the raise from 212 to 1317 products (nearly 521%) between 2006 and 2011 [3]. On the other hand, Nanomedicine is the emerging discipline that employs nanoobjects as tools to solve medical problems [4,5]. The volume market of Nanomedicine is expected to exceed $160 billion by 2015, according to a business report recently launched by the Global Industry Analysts Inc [6]. The main technological platform of Nanomedicine is nano-drug delivery, accounting for 78 % global sales and 58 % of patent filling worldwide [7,8] followed by development of nano-objects for in vitro/in vivo diagnosis [9] and tissue engineering [10]. The field is characterized by the advent of a different type of nano-objects, inherently dispersive or ‘free’.
Fil: Romero, Eder Lilia. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Diseño de Estrategias de Targeting de Drogas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
description Nanotechnology encompasses a broad conjunct of techniques aimed to engineer, characterize and make use of structures of 1 (nanoplates), 2 (nanotubes) or 3 dimensions (nanoparticles) in the nanoscale, known as nano-objects. The upper limit of the nanoscale was fixed at 100 nm [1], but in the nanopharmaceutical field the nano-scale is accepted to rise up to 200-300 nm. Biosynthesized molecules (such as hormones, proteins, nucleic acids) and drugs, whose activity depends on a primary structure and not on new phenomena derived from its size in the nano-scale, do not fit into the definition of nano-object [2]. Also the lower limit of the nanoscale was fixed in 1 nm in order to exclude atoms [2]. Beyond these constraints, there is no restriction in chemical nature of nano-objects. Today, the global market of nanotechnological consumer product is gained by non biodegradable and mostly nondispersive nano-objects. This is underscored by the raise from 212 to 1317 products (nearly 521%) between 2006 and 2011 [3]. On the other hand, Nanomedicine is the emerging discipline that employs nanoobjects as tools to solve medical problems [4,5]. The volume market of Nanomedicine is expected to exceed $160 billion by 2015, according to a business report recently launched by the Global Industry Analysts Inc [6]. The main technological platform of Nanomedicine is nano-drug delivery, accounting for 78 % global sales and 58 % of patent filling worldwide [7,8] followed by development of nano-objects for in vitro/in vivo diagnosis [9] and tissue engineering [10]. The field is characterized by the advent of a different type of nano-objects, inherently dispersive or ‘free’.
publishDate 2012
dc.date.none.fl_str_mv 2012-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/195353
Romero, Eder Lilia; The Involvement of Nano-Drug Delivery in Biosafety Issues; OMICS GROUP; Biosafty; 1; 2; 3-2012; 1-5
2167-0331
CONICET Digital
CONICET
url http://hdl.handle.net/11336/195353
identifier_str_mv Romero, Eder Lilia; The Involvement of Nano-Drug Delivery in Biosafety Issues; OMICS GROUP; Biosafty; 1; 2; 3-2012; 1-5
2167-0331
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.longdom.org/open-access/the-involvement-of-nanodrug-delivery-in-biosafety-issues-2167-0331.1000e108.pdf
info:eu-repo/semantics/altIdentifier/doi/10.4172/2167-0331.1000e108
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv OMICS GROUP
publisher.none.fl_str_mv OMICS GROUP
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269452310151168
score 13.13397